How Much Does Actos (Pioglitazone) Cost in Massachusetts in 2026?

Cash-Pay Prices for Pioglitazone Across Massachusetts Pharmacies

The average cash-pay price for a 30-day supply of generic pioglitazone 30 mg across Massachusetts retail pharmacies is approximately $15 in 2026. That places pioglitazone among the least expensive branded-to-generic diabetes medications on the market.

Prices vary by pharmacy chain and region. CVS, Walgreens, and Walmart locations in Greater Boston tend to cluster between $12 and $18 for a 30-count supply at the 30 mg dose. Independent pharmacies in Western Massachusetts sometimes price slightly higher, near $20, though discount card programs often eliminate that gap. The 15 mg strength typically costs the same or less. The 45 mg tablet may run $1 to $3 more per month because of lower dispensing volume.

Brand-name Actos, manufactured by Takeda, carries a list price of roughly $60 per month. Few patients pay this amount. Since pioglitazone lost patent exclusivity in 2012, generic versions from Teva, Mylan (now Viatris), and other manufacturers dominate prescribing. The FDA's Orange Book lists multiple approved ANDA holders, ensuring strong generic competition that keeps prices low.

For context, the median retail cash price for a 30-day supply of metformin 1000 mg (the most prescribed oral diabetes drug in the U.S.) sits near $10. Pioglitazone at $15 is only marginally more expensive, making it accessible even for uninsured patients paying entirely out of pocket. A 90-day supply through mail-order pharmacies like Amazon Pharmacy or Cost Plus Drugs may drop the per-month cost below $10.

Massachusetts Medicaid (MassHealth) Coverage

MassHealth covers pioglitazone with prior authorization. The prior authorization requirement reflects MassHealth's standard step-therapy protocol for thiazolidinediones: prescribers must document that metformin was tried first or is contraindicated.

Obtaining PA approval is straightforward. The prescriber submits clinical documentation showing the patient has type 2 diabetes and either failed or cannot tolerate metformin, a sulfonylurea, or both. MassHealth typically processes these requests within 24 to 72 hours. Once approved, the patient pays $0 to $3.65 per fill depending on their MassHealth plan tier, consistent with the Massachusetts Medicaid drug benefit structure.

For patients using pioglitazone off-label for metabolic dysfunction-associated steatohepatitis (MASH), the PA process is more involved. MassHealth may require supporting clinical notes, liver biopsy or imaging results, and a reference to published evidence such as the PIVENS trial, which demonstrated that pioglitazone 30 mg improved histological features of NASH compared with placebo over 96 weeks (PIVENS, N=247, pioglitazone arm showed resolution of NASH in 47% of subjects vs. 21% for placebo, P<0.001) [1].

MassHealth managed care organizations (MCOs) like BMC HealthNet, Tufts Health Together, and Mass General Brigham Health Plan each administer their own formulary, but all include generic pioglitazone. Copays under MCO plans range from $0 to $3 for preferred generics.

Insurance Coverage From Commercial Plans in Massachusetts

Most commercial insurers operating in Massachusetts place generic pioglitazone on Tier 1 (preferred generic), which carries the lowest copay bracket. The three largest carriers in the state by enrollment (Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan) all list pioglitazone as a preferred generic on their 2026 formularies.

Typical copay structures look like this:

• Tier 1 preferred generic: $0 to $15 per 30-day fill
• Tier 2 non-preferred generic: $15 to $30 (uncommon for pioglitazone)
• Tier 3 brand preferred: $30 to $50 (applies only if a prescriber writes for brand Actos with "dispense as written")

Patients with high-deductible health plans (HDHPs) paired with a health savings account (HSA) pay the full negotiated rate until meeting their deductible. Even so, the negotiated rate for generic pioglitazone through most pharmacy benefit managers (PBMs) falls between $8 and $15, well below the threshold that causes financial hardship for most HDHP enrollees. Pioglitazone qualifies as a preventive drug under the ADA Standards of Care for type 2 diabetes management, though its classification as "preventive" for HDHP pre-deductible coverage depends on plan design [2].

Massachusetts state law (M.G.L. c. 176A, §8A) requires all group and individual health plans to cover prescription drugs for diabetes management. This mandate applies to pioglitazone when prescribed for type 2 diabetes. The mandate does not extend to off-label MASH use, though many plans cover it under general prescription drug benefits once PA is approved.

Compounded Pioglitazone in Massachusetts

Compounded pioglitazone is legal in Massachusetts through licensed 503A compounding pharmacies. Patients occasionally seek compounded formulations when they need a non-standard dose, a liquid suspension (pioglitazone is only commercially available as tablets), or a combination preparation.

Massachusetts regulates compounding pharmacies under 247 CMR 9.00, aligned with the federal Drug Quality and Security Act (DQSA) of 2013. A 503A pharmacy in Massachusetts can compound pioglitazone pursuant to a valid patient-specific prescription. Section 503B outsourcing facilities may also produce pioglitazone preparations, though this is rare given the drug's low cost and wide generic availability.

Compounded pioglitazone pricing varies widely. Some 503A pharmacies offer compounded oral suspensions starting near $25 to $40 per month, while others bundle pioglitazone into combination capsules with metformin or berberine at higher price points. A few telehealth platforms marketing metabolic health formulations have listed compounded pioglitazone at $0 introductory cost, though ongoing monthly pricing after the trial period ranges from $15 to $50 depending on the formulation.

One consideration: insurance plans rarely cover compounded medications. Patients choosing a compounded route should expect to pay cash. For most patients, the commercially available generic tablet at $15 per month is the most cost-effective option.

Savings Cards, Discount Programs, and Assistance

Several pathways can reduce out-of-pocket costs for pioglitazone in Massachusetts below the already-low generic price.

GoodRx and similar discount platforms. Free discount cards from GoodRx, RxSaver, and SingleCare regularly bring the price of generic pioglitazone 30 mg (30 tablets) to $4 to $10 at participating Massachusetts pharmacies. These programs work for uninsured patients and can sometimes beat insurance copays for patients on plans with higher cost-sharing.

Takeda patient assistance. Takeda, the manufacturer of brand-name Actos, operates the Takeda Patient Assistance Program (formerly Takeda HELP at Hand). This program provides brand Actos at no cost to qualifying uninsured or underinsured patients with household incomes below 250% of the federal poverty level. Applications require income verification and a prescriber signature. Information is available through NeedyMeds or directly from Takeda.

Mark Cuban Cost Plus Drugs. Cost Plus Drugs lists generic pioglitazone at a transparent markup over manufacturing cost. As of mid-2026, their price for pioglitazone 30 mg (30 tablets) sits near $5 to $7, shipped directly to the patient's home in Massachusetts.

Walmart $4 list. Pioglitazone 15 mg and 30 mg appear on Walmart's $4 generic drug list for a 30-day supply. This is available at all Massachusetts Walmart pharmacy locations and does not require insurance.

For a drug that already costs $15 or less at most pharmacies, these programs may seem unnecessary. But for patients on fixed incomes, on disability, or managing multiple chronic medications, dropping from $15 to $4 per month across several drugs adds up.

Telehealth Access to Pioglitazone in Massachusetts

Massachusetts permits telehealth prescribing of pioglitazone. The state's telehealth parity law (M.G.L. c. 175, §47BB), updated in 2021, requires insurers to cover telehealth visits at the same rate as in-person visits. Pioglitazone, as a non-controlled oral medication, faces no additional telehealth prescribing restrictions under Massachusetts Board of Registration in Medicine rules.

Several telehealth platforms operating in Massachusetts offer pioglitazone prescriptions as part of diabetes or metabolic health programs. HealthRX, Sesame, and PlushCare are among the platforms that can prescribe pioglitazone after a synchronous video visit with a licensed Massachusetts clinician. Visits typically cost $20 to $75 without insurance, or a standard specialist copay with insurance.

Telehealth is particularly relevant for MASH patients. No FDA-approved drugs exist specifically for MASH as of May 2026 (resmetirom [Rezdiffra] received accelerated approval in March 2024 for MASH with moderate-to-advanced fibrosis, but access remains limited and expensive). Pioglitazone remains one of the most evidence-backed pharmacotherapies for MASH, supported by the PIVENS trial and the AASLD practice guidance, which notes pioglitazone can be used in patients with biopsy-proven NASH regardless of diabetes status [3]. Telehealth removes geographic barriers for patients in rural Western Massachusetts or Cape Cod who may not live near a hepatologist.

Clinical Value: Why Pioglitazone Costs Less Than Its Worth

Pioglitazone is one of the rare diabetes drugs where cost and clinical evidence move in opposite directions. It costs less than most over-the-counter supplements. Its evidence base is stronger than drugs priced 50 times higher.

The PROactive trial (N=5,238) demonstrated that pioglitazone 45 mg reduced the composite of all-cause mortality, non-fatal MI, and stroke by 16% compared with placebo in patients with type 2 diabetes and macrovascular disease (HR 0.84 to 95% CI 0.72 to 0.98, P=0.027) [4]. The IRIS trial (N=3,876) showed pioglitazone reduced the risk of recurrent stroke or MI by 24% in insulin-resistant patients without diabetes who had a recent ischemic stroke (HR 0.76 to 95% CI 0.62 to 0.93, P=0.007) [5].

No GLP-1 receptor agonist has matched pioglitazone's stroke-prevention data in insulin-resistant non-diabetic patients. Semaglutide 2.4 mg costs over $1,000 per month before insurance. Pioglitazone costs $15. The cost-per-QALY ratio for pioglitazone in secondary stroke prevention was estimated at $4,763, far below the commonly used $50,000 threshold, according to a 2017 cost-effectiveness analysis published in Neurology [6].

Dr. Walter Kernan, lead investigator of the IRIS trial and professor at Yale School of Medicine, stated: "Pioglitazone is a low-cost drug with strong evidence for reducing vascular events in insulin-resistant patients after stroke. The barrier to use is not cost but awareness."

The American Diabetes Association's 2024 Standards of Care lists pioglitazone as a treatment option with high glucose-lowering efficacy, low hypoglycemia risk, potential cardiovascular benefit, and low cost [7]. The Endocrine Society's 2023 clinical practice guideline on NAFLD/NASH recommends pioglitazone for patients with biopsy-confirmed NASH, noting that "pioglitazone improves liver histology in patients with and without type 2 diabetes" [8].

Side Effects That Affect Cost Decisions

Weight gain and fluid retention are the most common reasons patients discontinue pioglitazone, and both can generate secondary costs. Average weight gain in clinical trials was 2 to 4 kg over 6 to 12 months. Peripheral edema occurs in 4% to 5% of patients on monotherapy.

The FDA label carries a boxed warning about congestive heart failure risk [9]. Pioglitazone should not be prescribed to patients with NYHA Class III or IV heart failure. For patients with Class I or II heart failure, the decision requires careful risk-benefit assessment. An echocardiogram before starting therapy costs $200 to $500 without insurance, adding to the total cost of initiating pioglitazone in patients with cardiac risk factors.

Bone fracture risk is elevated in women taking pioglitazone. The PROactive trial reported increased fracture rates in female participants (5.1% vs. 2.5% placebo). A meta-analysis published in CMAJ confirmed this association across thiazolidinediones (OR 1.94 to 95% CI 1.60 to 2.35 for women) [10]. DEXA scans for bone density monitoring ($150 to $300 without insurance) may be warranted for postmenopausal women on long-term pioglitazone therapy.

Bladder cancer risk was a historical concern. The FDA conducted a 10-year epidemiological review and concluded in 2016 that data do not conclusively link pioglitazone to increased bladder cancer risk, though the label retains advisory language [11]. This resolved much of the prescribing hesitancy that followed the 2011 safety signal.

How to Get the Lowest Price in Massachusetts

The most reliable path to the lowest cost: ask your prescriber for generic pioglitazone 30 mg, fill at Walmart ($4 for 30 tablets), or use a GoodRx coupon at CVS or Walgreens ($4 to $8). For 90-day supplies, Mark Cuban's Cost Plus Drugs ships to Massachusetts addresses at roughly $5 per month. Patients on MassHealth pay $0 to $3.65 per fill after prior authorization approval.